Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer

뉴스 본문을 불러오고 있어요.

Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer | 웨이프 WAPE

Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer

기사 요약

관련 종목

댓글 —